Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes
NCT ID: NCT05979415
Last Updated: 2025-10-21
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
PHASE2
Total Enrollment
8 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-09-27
Study Completion Date
2024-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will be conducted with In-clinic visits and treatment at home for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease
NCT04157933
Parkinson's Disease
COMPLETED
PHASE1
Staccato Apomorphine Single and Multi Dose PK
NCT03822364
Parkinson Disease
COMPLETED
PHASE1
Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
NCT00986414
Parkinson Disease
Dyskinesias
COMPLETED
PHASE2
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
NCT02469090
Parkinson Disease, Off Episodes
COMPLETED
PHASE3
Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease
NCT00200525
Parkinson Disease
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose of this protocol is to establish the safety, tolerability, and efficacy of AZ-009 compared to placebo in patients with established PD experiencing daily OFF episodes.
Patients between the ages of 30 and 85 with a clinical diagnosis of established PD who experience motor fluctuation and have recognizable OFF periods are eligible for participation in this study. The patients will be classified as Modified Hoehn \& Yahr stage II-IV in the ON state and have clear, self-described daily motor fluctuations while on oral l-dopa or Carbidopa (with or without adjunctive PD therapy).
This study will be conducted in approximately 50 patients, with up to 8 Open-Label titration in-clinic visits with treatment at home between visits. This is followed by Double Blind which includes a 13 day treatment at home period, and an in-clinic visit and an End of Study/Early Termination visit for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes.
Patients between the ages of 30 and 85 with a clinical diagnosis of established PD who experience motor fluctuation and have recognizable OFF periods are eligible for participation in this study. The patients will be classified as Modified Hoehn \& Yahr stage II-IV in the ON state and have clear, self-described daily motor fluctuations while on oral l-dopa or Carbidopa (with or without adjunctive PD therapy).
This study will be conducted in approximately 50 patients, with up to 8 Open-Label titration in-clinic visits with treatment at home between visits. This is followed by Double Blind which includes a 13 day treatment at home period, and an in-clinic visit and an End of Study/Early Termination visit for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Parkinson Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Blinded
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Staccato Apomorphine
1mg, 2mg, 3mg, 4mg
Group Type
ACTIVE_COMPARATOR
Apomorphine Cartridge
Intervention Type
DRUG
Staccato Cartridge
Staccato Placebo
Placebo
Group Type
PLACEBO_COMPARATOR
Apomorphine Cartridge
Intervention Type
DRUG
Staccato Cartridge
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Apomorphine Cartridge
Staccato Cartridge
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 1\. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
2\. Willing and able to travel to the clinical research center and adhere to the overall study visit schedule, procedures, and other protocol requirements.
3\. Male or female between the ages of 30 and 85 (inclusive). 4. Body weight ≥ 50 kg. 5. Willing to abstain from alcohol for 6 hours prior to a study visit and minimize alcohol use throughout the study duration.
6\. Have a clinical diagnosis of PD; with fulfillment of Steps 1 and 2 of the UK Parkinson's Disease Brain Bank Criteria.
7\. Optimized and stabilized on oral dopaminergic therapy including levodopa at least 3 times daily and in combination with decarboxylase inhibitor at least 30 days prior to screening.
8\. Classified as Modified Hoehn \& Yahr stage II-IV in the ON state at Visit 1. 9. Have an MDS-UPDRS III score of at least 30 in the OFF state prior to the L-dopa challenge at Visit 2.
10\. Experience self-described motor fluctuations (confirmed by the Motor Fluctuation Questionnaire at Screening) with recognizable OFF periods while on optimized oral l-dopa or dopamine agonist therapy.
11\. Experience at least 2 hours of OFF time per day and show responsiveness to levodopa (defined by a ≥ 30% reduction in MDS-UPDRS III score compared to pre-dose) at Visit 2.
12\. Female subjects, who are not pregnant or breastfeeding, and one of the following conditions applies: 13. Surgically sterile (including bilateral tubal ligation) for at least 3 months prior to screening.
* Postmenopausal, defined as 1 of the following:
* Last menstrual sequence greater than 12 months prior to screening
* Last menstrual sequence greater than 6 months prior to screening and a serum follicle-stimulating hormone (FSH) concentration \> 40 mIU/mL
* Of childbearing potential (i.e., do not meet the criteria outlined above), patient must:
* Have a negative urine pregnancy test at Screening and Day -1, as verified by the study doctor prior to starting study therapy.
* Either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with, effective contraception without interruption with one of the following methods during the study participation up until 30 days after administration of study drug:
* Oral contraceptive medications; Intra uterine devices; Hormonal implants; Injectable contraceptive medications; Double-barrier methods 14. Male subjects must practice true abstinence from heterosexual contact or, during sexual contact with a pregnant female or a female of childbearing potential, agree to use a condom or have had vasectomy with negative semen analysis and refrain from sperm donation during the duration of the study and up to 90 days after last dose of study drug.
1. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
2. Willing and able to travel to the clinical research center and adhere to the overall study visit schedule, procedures, and other protocol requirements.
3. Male or female between the ages of 30 and 85 (inclusive).
4. Body weight ≥ 50 kg.
5. Willing to abstain from alcohol for 6 hours prior to a study visit and minimize alcohol use throughout the study duration.
6. Have a clinical diagnosis of PD; with fulfillment of Steps 1 and 2 of the UK Parkinson's Disease Brain Bank Criteria.
7. Optimized and stabilized on oral dopaminergic therapy including levodopa at least 3 times daily and in combination with decarboxylase inhibitor at least 30 days prior to screening.
8. Classified as Modified Hoehn \& Yahr stage II-IV in the ON state at Visit 1.
9. Have an MDS-UPDRS III score of at least 30 in the OFF state prior to the L-dopa challenge at Visit 2.
10. Experience self-described motor fluctuations (confirmed by the Motor Fluctuation Questionnaire at Screening) with recognizable OFF periods while on optimized oral l-dopa or dopamine agonist therapy.
11. Experience at least 2 hours of OFF time per day and show responsiveness to levodopa (defined by a ≥ 30% reduction in MDS-UPDRS III score compared to pre-dose) at Visit 2.
12. Female subjects, who are not pregnant or breastfeeding, and one of the following conditions applies:
13. Surgically sterile (including bilateral tubal ligation) for at least 3 months prior to screening.
* Postmenopausal, defined as 1 of the following:
* Last menstrual sequence greater than 12 months prior to screening
* Last menstrual sequence greater than 6 months prior to screening and a serum follicle-stimulating hormone (FSH) concentration \> 40 mIU/mL
* Of childbearing potential (i.e., do not meet the criteria outlined above), patient must:
* Have a negative urine pregnancy test at Screening and Day -1, as verified by the study doctor prior to starting study therapy.
* Either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with, effective contraception without interruption with one of the following methods during the study participation up until 30 days after administration of study drug:
* Oral contraceptive medications; Intra uterine devices; Hormonal implants; Injectable contraceptive medications; Double-barrier methods
14. Male subjects must practice true abstinence from heterosexual contact or, during sexual contact with a pregnant female or a female of childbearing potential, agree to use a condom or have had vasectomy with negative semen analysis and refrain from sperm donation during the duration of the study and up to 90 days after last dose of study drug.
2\. Willing and able to travel to the clinical research center and adhere to the overall study visit schedule, procedures, and other protocol requirements.
3\. Male or female between the ages of 30 and 85 (inclusive). 4. Body weight ≥ 50 kg. 5. Willing to abstain from alcohol for 6 hours prior to a study visit and minimize alcohol use throughout the study duration.
6\. Have a clinical diagnosis of PD; with fulfillment of Steps 1 and 2 of the UK Parkinson's Disease Brain Bank Criteria.
7\. Optimized and stabilized on oral dopaminergic therapy including levodopa at least 3 times daily and in combination with decarboxylase inhibitor at least 30 days prior to screening.
8\. Classified as Modified Hoehn \& Yahr stage II-IV in the ON state at Visit 1. 9. Have an MDS-UPDRS III score of at least 30 in the OFF state prior to the L-dopa challenge at Visit 2.
10\. Experience self-described motor fluctuations (confirmed by the Motor Fluctuation Questionnaire at Screening) with recognizable OFF periods while on optimized oral l-dopa or dopamine agonist therapy.
11\. Experience at least 2 hours of OFF time per day and show responsiveness to levodopa (defined by a ≥ 30% reduction in MDS-UPDRS III score compared to pre-dose) at Visit 2.
12\. Female subjects, who are not pregnant or breastfeeding, and one of the following conditions applies: 13. Surgically sterile (including bilateral tubal ligation) for at least 3 months prior to screening.
* Postmenopausal, defined as 1 of the following:
* Last menstrual sequence greater than 12 months prior to screening
* Last menstrual sequence greater than 6 months prior to screening and a serum follicle-stimulating hormone (FSH) concentration \> 40 mIU/mL
* Of childbearing potential (i.e., do not meet the criteria outlined above), patient must:
* Have a negative urine pregnancy test at Screening and Day -1, as verified by the study doctor prior to starting study therapy.
* Either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with, effective contraception without interruption with one of the following methods during the study participation up until 30 days after administration of study drug:
* Oral contraceptive medications; Intra uterine devices; Hormonal implants; Injectable contraceptive medications; Double-barrier methods 14. Male subjects must practice true abstinence from heterosexual contact or, during sexual contact with a pregnant female or a female of childbearing potential, agree to use a condom or have had vasectomy with negative semen analysis and refrain from sperm donation during the duration of the study and up to 90 days after last dose of study drug.
1. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
2. Willing and able to travel to the clinical research center and adhere to the overall study visit schedule, procedures, and other protocol requirements.
3. Male or female between the ages of 30 and 85 (inclusive).
4. Body weight ≥ 50 kg.
5. Willing to abstain from alcohol for 6 hours prior to a study visit and minimize alcohol use throughout the study duration.
6. Have a clinical diagnosis of PD; with fulfillment of Steps 1 and 2 of the UK Parkinson's Disease Brain Bank Criteria.
7. Optimized and stabilized on oral dopaminergic therapy including levodopa at least 3 times daily and in combination with decarboxylase inhibitor at least 30 days prior to screening.
8. Classified as Modified Hoehn \& Yahr stage II-IV in the ON state at Visit 1.
9. Have an MDS-UPDRS III score of at least 30 in the OFF state prior to the L-dopa challenge at Visit 2.
10. Experience self-described motor fluctuations (confirmed by the Motor Fluctuation Questionnaire at Screening) with recognizable OFF periods while on optimized oral l-dopa or dopamine agonist therapy.
11. Experience at least 2 hours of OFF time per day and show responsiveness to levodopa (defined by a ≥ 30% reduction in MDS-UPDRS III score compared to pre-dose) at Visit 2.
12. Female subjects, who are not pregnant or breastfeeding, and one of the following conditions applies:
13. Surgically sterile (including bilateral tubal ligation) for at least 3 months prior to screening.
* Postmenopausal, defined as 1 of the following:
* Last menstrual sequence greater than 12 months prior to screening
* Last menstrual sequence greater than 6 months prior to screening and a serum follicle-stimulating hormone (FSH) concentration \> 40 mIU/mL
* Of childbearing potential (i.e., do not meet the criteria outlined above), patient must:
* Have a negative urine pregnancy test at Screening and Day -1, as verified by the study doctor prior to starting study therapy.
* Either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with, effective contraception without interruption with one of the following methods during the study participation up until 30 days after administration of study drug:
* Oral contraceptive medications; Intra uterine devices; Hormonal implants; Injectable contraceptive medications; Double-barrier methods
14. Male subjects must practice true abstinence from heterosexual contact or, during sexual contact with a pregnant female or a female of childbearing potential, agree to use a condom or have had vasectomy with negative semen analysis and refrain from sperm donation during the duration of the study and up to 90 days after last dose of study drug.
Exclusion Criteria
1. Previous significant complications from oral dopamine agonist therapy including hospitalization, hallucinations, or any other clinically relevant neuropsychiatric adverse event. Known intolerance to apomorphine.
2. Inhaled or sublingual apomorphine or inhaled l-dopa treatments during the trial.
3. Expected use of Apokyn or Kynmobi during the titration and treatment phase of the study.
4. Participation in earlier AZ-009 clinical trials.
5. Patients with suicidal behavior occurring within the past year or who pose a current suicide risk as determined by the PI or as confirmed at the first Screening Visit, the L-dopa challenge Visit (Visit -2) or Day 1 (Visit 3) by affirmative answer on items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS).
6. Symptomatic clinically relevant and medically uncontrolled orthostatic hypotension or systolic blood pressure less than 100 mmHg at Screening or Baseline. Orthostatic hypotension is defined as a decrease in systolic blood pressure of 20 mm Hg \> or a decrease in diastolic blood pressure \> 10 mm Hg, or increase in heart rate \> 20 BPM, when standing compared with blood pressure from the supine position.
7. Any clinically significant or unstable medical or psychiatric condition, as determined by the PI, based on a medical evaluation including history, physical examination, vital signs, electrocardiograms (ECGs), and laboratory tests assessed at the screening visit and prior to the first dose of study drug that could compromise the participant's safety or interfere with the completion of this protocol. A patient with a non-clinically significant abnormality or laboratory parameters outside the reference range may continue with the approval of the Investigator.
8. Subjects with a prolonged QT interval corrected for heart rate according to Fridericia's formula (QTcF) of \>450 ms for male and \>470 ms for female at screening or directly prior to first dosing, or a history of long QT syndrome. Also subjects with a PR interval \> 220 msec or QRS duration \> 120 msec at screening.
9. Currently taking, or may need treatment with, nitroglycerine
10. Any documented active or suspected or history of malignancy within 5 years prior to Visit 1, except appropriately treated basal cell carcinoma.
11. Active hallucinations or history of hallucinations in the past 3 months. Any significant medical condition, psychiatric illness, current major uncontrolled depression or bipolar disease, or history of depression that could, in the investigator's opinion, compromise the subject's safety or interfere with the completion of this protocol.
12. Dementia indicated by MMSE \<24 at Screening.
13. History of clinically significant central nervous system (e.g., seizures), cardiac, pulmonary (e.g., asthma, COPD), metabolic, renal, hepatic, or gastrointestinal (GI) conditions including gastric bypass or other weight loss surgical procedure; or history of such conditions that, in the opinion of the investigator, may place the subject at an unacceptable risk as a participant in this trial, may interfere with the interpretation of safety and/or tolerability data obtained in the trial, or may interfere with the absorption, distribution, metabolism, or excretion of the study drugs.
14. Screening FEV1 \< 50% of predicted or FEV1/FVC ratio \< 60% in the ON state at Visit 1.
15. Any condition including the presence of laboratory abnormalities, which according to the investigator places the subject at unacceptable risk if he/she were to participate in the study.
16. Aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT), serum creatinine, or total bilirubin \> 1.5 x upper limit of normal (ULN) at screening or prior to the first dose of study drug. An exception may be made for suspected Gilbert's syndrome. These laboratory tests may be repeated once, if they are abnormal on first screening, and if there is a medical reason to believe the results may be inaccurate. If the repeat test is within the reference range, the subject may be included only if the investigator considers that the previous finding will not compromise the subject's safety and will not interfere with the interpretation of safety data.
17. Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen, or hepatitis C virus antibody at screening.
18. History of drug or alcohol abuse within 6 months of screening.
19. Positive drug screen at baseline. May not be exclusionary with a prescription.
20. History of any smoking/vaping (tobacco, cannabinoids) or any tobacco product use within 3 months prior to the study.
21. Participation in a clinical trial and receipt of an investigational medication or a new chemical entity within 30 days, 5 half-lives, if known, or twice the duration of the biological effect of any medication (whichever is longer) prior to the first dose of current study drug.
22. Use of medication that is inhibitor or inducer of CYP450-3A4/5 within 3 days of dosing.
23. Donation of blood, plasma or other blood products or blood collection in excess of 470 mL within 8 weeks prior to dosing.
24. Known sensitivity to any of the study drugs or components thereof, or a history of medication allergy or other allergy that, in the opinion of the investigator, contraindicates study participation.
25. Major surgery within 4 weeks of screening that could interfere with, or for which the treatment might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator.
26. Use of 5HT3 antagonists, including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) and alosetron during the trial.
27. Medications to treat gastroparesis (Antiemetics) or any dopamine antagonist.
2. Inhaled or sublingual apomorphine or inhaled l-dopa treatments during the trial.
3. Expected use of Apokyn or Kynmobi during the titration and treatment phase of the study.
4. Participation in earlier AZ-009 clinical trials.
5. Patients with suicidal behavior occurring within the past year or who pose a current suicide risk as determined by the PI or as confirmed at the first Screening Visit, the L-dopa challenge Visit (Visit -2) or Day 1 (Visit 3) by affirmative answer on items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS).
6. Symptomatic clinically relevant and medically uncontrolled orthostatic hypotension or systolic blood pressure less than 100 mmHg at Screening or Baseline. Orthostatic hypotension is defined as a decrease in systolic blood pressure of 20 mm Hg \> or a decrease in diastolic blood pressure \> 10 mm Hg, or increase in heart rate \> 20 BPM, when standing compared with blood pressure from the supine position.
7. Any clinically significant or unstable medical or psychiatric condition, as determined by the PI, based on a medical evaluation including history, physical examination, vital signs, electrocardiograms (ECGs), and laboratory tests assessed at the screening visit and prior to the first dose of study drug that could compromise the participant's safety or interfere with the completion of this protocol. A patient with a non-clinically significant abnormality or laboratory parameters outside the reference range may continue with the approval of the Investigator.
8. Subjects with a prolonged QT interval corrected for heart rate according to Fridericia's formula (QTcF) of \>450 ms for male and \>470 ms for female at screening or directly prior to first dosing, or a history of long QT syndrome. Also subjects with a PR interval \> 220 msec or QRS duration \> 120 msec at screening.
9. Currently taking, or may need treatment with, nitroglycerine
10. Any documented active or suspected or history of malignancy within 5 years prior to Visit 1, except appropriately treated basal cell carcinoma.
11. Active hallucinations or history of hallucinations in the past 3 months. Any significant medical condition, psychiatric illness, current major uncontrolled depression or bipolar disease, or history of depression that could, in the investigator's opinion, compromise the subject's safety or interfere with the completion of this protocol.
12. Dementia indicated by MMSE \<24 at Screening.
13. History of clinically significant central nervous system (e.g., seizures), cardiac, pulmonary (e.g., asthma, COPD), metabolic, renal, hepatic, or gastrointestinal (GI) conditions including gastric bypass or other weight loss surgical procedure; or history of such conditions that, in the opinion of the investigator, may place the subject at an unacceptable risk as a participant in this trial, may interfere with the interpretation of safety and/or tolerability data obtained in the trial, or may interfere with the absorption, distribution, metabolism, or excretion of the study drugs.
14. Screening FEV1 \< 50% of predicted or FEV1/FVC ratio \< 60% in the ON state at Visit 1.
15. Any condition including the presence of laboratory abnormalities, which according to the investigator places the subject at unacceptable risk if he/she were to participate in the study.
16. Aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT), serum creatinine, or total bilirubin \> 1.5 x upper limit of normal (ULN) at screening or prior to the first dose of study drug. An exception may be made for suspected Gilbert's syndrome. These laboratory tests may be repeated once, if they are abnormal on first screening, and if there is a medical reason to believe the results may be inaccurate. If the repeat test is within the reference range, the subject may be included only if the investigator considers that the previous finding will not compromise the subject's safety and will not interfere with the interpretation of safety data.
17. Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen, or hepatitis C virus antibody at screening.
18. History of drug or alcohol abuse within 6 months of screening.
19. Positive drug screen at baseline. May not be exclusionary with a prescription.
20. History of any smoking/vaping (tobacco, cannabinoids) or any tobacco product use within 3 months prior to the study.
21. Participation in a clinical trial and receipt of an investigational medication or a new chemical entity within 30 days, 5 half-lives, if known, or twice the duration of the biological effect of any medication (whichever is longer) prior to the first dose of current study drug.
22. Use of medication that is inhibitor or inducer of CYP450-3A4/5 within 3 days of dosing.
23. Donation of blood, plasma or other blood products or blood collection in excess of 470 mL within 8 weeks prior to dosing.
24. Known sensitivity to any of the study drugs or components thereof, or a history of medication allergy or other allergy that, in the opinion of the investigator, contraindicates study participation.
25. Major surgery within 4 weeks of screening that could interfere with, or for which the treatment might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator.
26. Use of 5HT3 antagonists, including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) and alosetron during the trial.
27. Medications to treat gastroparesis (Antiemetics) or any dopamine antagonist.
Minimum Eligible Age
30 Years
Maximum Eligible Age
85 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peachtree BioResearch Solutions Inc.
UNKNOWN
Sponsor Role
collaborator
DSG, Inc
UNKNOWN
Sponsor Role
collaborator
ISS, Inc.
INDUSTRY
Sponsor Role
collaborator
Alexza Pharmaceuticals, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Movement Disorders Center of Arizona
Scottsdale, Arizona, United States
Site Status
Tuscon Neuroscience Research (M3 Wake Research)
Tucson, Arizona, United States
Site Status
The Parkinson's and Movement Disorder Institute
Fountain Valley, California, United States
Site Status
Cenexel Rocky Mountain Clinical Research
Englewood, Colorado, United States
Site Status
Bradenton Research Center, Inc.
Bradenton, Florida, United States
Site Status
Holy Cross Health
Fort Lauderdale, Florida, United States
Site Status
Visionary Investigators Network
Miami, Florida, United States
Site Status
Parkinson's Disease Treatment Center of Southwest Florida
Port Charlotte, Florida, United States
Site Status
CenExel iResearch Atlanta (Decatur)
Decatur, Georgia, United States
Site Status
Quest Research Institute
Farmington Hills, Michigan, United States
Site Status
Accellacare of Piedmont Healthcare
Statesville, North Carolina, United States
Site Status
KCA Neurology, (Part of Ki Health Partners, LLC)
Franklin, Tennessee, United States
Site Status
Lone Star Neurology, (Part of Ki Health Partners, LLC)
Frisco, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMDC 009-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia
NCT01092065
COMPLETED
PHASE2
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
NCT02687542
TERMINATED
PHASE2
Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months
NCT00200512
COMPLETED
PHASE2/PHASE3
Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease
NCT02006121
COMPLETED
PHASE3
Infusion of Apomorphine: Long-term Safety Study
NCT02339064
ACTIVE_NOT_RECRUITING
PHASE3
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
NCT01603069
COMPLETED
PHASE2
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients
NCT00888004
COMPLETED
PHASE2
Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease
NCT00142545
COMPLETED
PHASE3
Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
NCT01385592
COMPLETED
PHASE2
A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes
NCT03292016
COMPLETED
PHASE2
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
NCT02565628
COMPLETED
PHASE1
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
NCT01491529
COMPLETED
PHASE2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease
NCT02224664
COMPLETED
PHASE1
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
NCT01173731
COMPLETED
PHASE2
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
NCT02373072
COMPLETED
PHASE1
A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients
NCT02605434
UNKNOWN
PHASE3
Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
NCT03185481
TERMINATED
PHASE2
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
NCT02542696
COMPLETED
PHASE3
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa
NCT00582673
COMPLETED
PHASE2
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
NCT02847650
TERMINATED
PHASE2
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
NCT00357994
COMPLETED
PHASE3
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
NCT02240030
COMPLETED
PHASE3
Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease
NCT02267434
COMPLETED
PHASE1